← Back to Search

Monoclonal Antibodies

Combination Product: Nivolumab with Pemetrexed for Squamous Cell Carcinoma (NivoPlus Trial)

Phase 2
Waitlist Available
Led By Hatim Karachiwala, MD FRCPC
Research Sponsored by AHS Cancer Control Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years from final study drug dose.
Awards & highlights

NivoPlus Trial Summary

This trial is testing a new cancer treatment combination to see if it is effective and safe.

Eligible Conditions
  • Squamous Cell Carcinoma

NivoPlus Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years from final study drug dose.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years from final study drug dose. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility
Safety/tolerability (incidence of adverse events including immune related)
Secondary outcome measures
Overall Survival
Patient reported quality of life
Progression free survival
+1 more
Other outcome measures
Investigation of the role of CD71+ immature red blood cells in the response to treatment with immunotherapy

NivoPlus Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
A single-arm combining nivolumab with pemetrexed

Find a Location

Who is running the clinical trial?

Alberta Cancer FoundationOTHER
17 Previous Clinical Trials
5,613 Total Patients Enrolled
AHS Cancer Control AlbertaLead Sponsor
182 Previous Clinical Trials
36,192 Total Patients Enrolled
Hatim Karachiwala, MD FRCPCPrincipal InvestigatorAlberta Health Services - Cross Cancer Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
JAMA OncologyJournal
Evaluation and Regulation of Oncology Drug Approval
Lyman, Gary H.. 2016. “Evaluation and Regulation of Oncology Drug Approval”. JAMA Oncology. American Medical Association (AMA). doi:10.1001/jamaoncol.2015.6477.
New England Journal of MedicineJournal
Platinum-based Chemotherapy Plus Cetuximab in Head and Neck Cancer
Vermorken, Jan B., Ricard Mesia, Fernando Rivera, Eva Remenar, Andrzej Kawecki, Sylvie Rottey, Jozsef Erfan, et al.. 2008. “Platinum-based Chemotherapy Plus Cetuximab in Head and Neck Cancer”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa0802656.
Clinical Cancer ResearchJournal
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-related Response Criteria
Wolchok, Jedd D., Axel Hoos, Steven O'Day, Jeffrey S. Weber, Omid Hamid, Celeste Lebbé, Michele Maio, et al.. 2009. “Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-related Response Criteria”. Clinical Cancer Research. American Association for Cancer Research (AACR). doi:10.1158/1078-0432.ccr-09-1624.
JAMA OncologyJournal
Evaluation and Regulation of Oncology Drug Approval
Lyman, Gary H.. 2016. “Evaluation and Regulation of Oncology Drug Approval”. JAMA Oncology. American Medical Association (AMA). doi:10.1001/jamaoncol.2015.6477.
All > Squamous Cell Carcinoma
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top